XEOMIN
As listed in the register: XEOMIN
50 unit · powder for solution
- Prescription only
- Muscles, joints and bones
- Active substance
- Incobotulinumtoxina
- Used in
- Muscles, joints and bones
- Made by
- Merz Pharmaceuticals Gmbh
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Xeomin). It describes the substance, not this exact product.
XEOMIN blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve endings.
This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of SNAP25, a presynaptic target protein essential for the release of acetylcholine.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-10
Safety of the active substance
From the US prescribing label for the same active substance (Xeomin). It describes the substance, not this exact product.
WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.
- XEOMIN is contraindicated in patients with: Known hypersensitivity to any botulinum toxin product or to any of the components in the formulation [see Warnings and Precautions (5.3) and Description (11) ].
- Infection at the proposed injection site(s) because it could lead to severe local or disseminated infection.
- Known hypersensitivity to the active substance botulinum neurotoxin type A or to any of the excipients ( 4, 5.3 ) Infection at the proposed injection sites ( 4 )
The most common adverse reactions (≥4%) were tooth extraction, dry mouth, diarrhea, and hypertension.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Merz Pharmaceuticals Gmbh |
|---|---|
| Active substance | Incobotulinumtoxina |
| Used in | Muscles, joints and bones |
| Strength | 50 unit |
| Form | powder for solution |
| Classification | M03AX01 · Muscles, joints and bones |
| Route | intramuscular, intraglandular |
| Dispensing (as stated by the register) | SCHEDULE D · PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02371081 |
| DPD drug code | 85628 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.